LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Stock Chart & Stats
$9.90
-$0.43(-1.58%)
At close: 4:00 PM EST
$9.90
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$8.25 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)1.00M
Market Cap
$300.38M
Enterprise Value$275.55M
Total Cash (Recent Filing)$292.35M
Total Debt (Recent Filing)$350.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 13, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding31,354,395
10 Day Avg. Volume787,663
30 Day Avg. Volume1,003,983
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue14.44
Enterprise Value/Gross Profit14.89
Enterprise Value/Ebitda-3.10
Forecast
1Y Price Target
$36.01Price Target Upside263.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.72
Revenue Forecast (FY)$28.32M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationClinical data showing greater efficacy, faster onset, and longer durability across a broader patient group positions Vizz as a best-in-class presbyopia therapy and provides clear differentiation points for prescribers.
Marketing EffectivenessDirect-to-consumer marketing featuring a prominent spokesperson generated strong consumer engagement and increased website traffic, supporting potential expansion of demand as awareness grows.
Prescriber AdoptionInitial adoption by many eye care professionals with a high rate of repeat prescriptions indicates meaningful prescriber interest that could support sustained sales growth.
Bears Say
Competitive PressureA competitor securing financing strengthens its commercial-launch capability, increasing competition for market share and potentially pressuring pricing and uptake.
Revenue Ramp And Valuation RiskAnalyst reduced valuation and forecasts to reflect a slower-than-expected sales ramp, signaling upside risk to near-term revenue execution and the stock price.
Safety MonitoringReports of ocular adverse events, including retinal issues and transient eye redness, create investor caution and necessitate ongoing safety monitoring that could slow adoption.
LENZ Therapeutics News
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $8.25 and its highest was $50.40 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $300.38M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 27 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Mar 25, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$0.908 by -$0.252.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 31,354,395 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$1.16 in its last earnings report, missing expectations of -$0.908. Following the earnings report the stock price went up 0.443%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.01 (263.74% Upside)
$36.01 (263.74% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 763.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $365.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.40%
12-Months-Change
Fundamentals
Return on Equity
-37.47%
Trailing 12-Months
Asset Growth
42.07%
Trailing 12-Months
Company Description
LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: product efficacy and early real-world persistence plus strong physician awareness, encouraging prescriber productivity, expanding field coverage, and a robust cash balance are clear positives. However, the launch is capital-intensive with substantial SG&A increases and meaningful Q4 net loss, early-stage NRx growth due to deliberate sampling strategy and category education, limited short-term visibility on refill/conversion metrics, and a relatively low expected direct product gross margin. Management’s tone is constructive and execution-focused, positioning the company to scale adoption over the coming quarters while they absorb near-term investment-driven losses.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$36.01
▲(263.74% Upside)